Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
暂无分享,去创建一个
G. Mills | K. Do | F. Meric-Bernstam | Yun Wu | A. González-Angulo | C. Arteaga | A. Akcakanat | Huiqin Chen | T. Miller | T. Sangai | E. Tarco
[1] A. Laenkholm,et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012 .
[2] A. Laenkholm,et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Lucy Marum,et al. Cancer Cell Line Encyclopedia launched by Novartis and Broad Institute. , 2012, Future medicinal chemistry.
[4] G. Mills,et al. PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors , 2012, Clinical Cancer Research.
[5] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[6] J. Mayerle,et al. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. , 2012, Gastroenterology.
[7] M. Xing,et al. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. , 2012, The Journal of clinical endocrinology and metabolism.
[8] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Liao,et al. MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis , 2011, Molecular Cancer Therapeutics.
[10] B. Wittner,et al. Asymmetric cancer cell division regulated by AKT , 2011, Proceedings of the National Academy of Sciences.
[11] K. Coombes,et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.
[12] D. Coppola,et al. Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice , 2011, Clinical Cancer Research.
[13] G. Mills,et al. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011, Molecular Cancer Therapeutics.
[14] Kuen-Feng Chen,et al. Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells , 2011, Journal of Pharmacology and Experimental Therapeutics.
[15] G. Robertson,et al. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. , 2011, Cancer research.
[16] A. Toker,et al. Akt2 regulates expression of the actin‐bundling protein palladin , 2010, FEBS letters.
[17] Michael Peyton,et al. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.
[18] G. Mills,et al. Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer , 2010, Molecular Cancer Therapeutics.
[19] G. Mills,et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.
[20] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[21] A. Toker,et al. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. , 2010, Molecular cell.
[22] Mingming Jia,et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..
[23] S. Tsavachidis,et al. The rapamycin-regulated gene expression signature determines prognosis for breast cancer , 2009, Molecular Cancer.
[24] P. Pandolfi,et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.
[25] Yiling Lu,et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.
[26] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[27] T. McGraw,et al. Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling , 2009, Proceedings of the National Academy of Sciences.
[28] A. Toker,et al. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction , 2009, Nature Cell Biology.
[29] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[30] F. Meric-Bernstam,et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. , 2007, Endocrine-related cancer.
[31] L. Saal,et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.
[32] Yiling Lu,et al. Pharmacodynamic Markers of Perifosine Efficacy , 2007, Clinical Cancer Research.
[33] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[34] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[35] Marc-André Elsliger,et al. Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.
[36] A. Newton,et al. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.
[37] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[38] Brian A. Hemmings,et al. Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding , 2006, Molecular and Cellular Biology.
[39] H. Koistinen,et al. siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. , 2006, Cell metabolism.
[40] Frank McCormick,et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.
[41] Fred A. Wright,et al. Practical FDR-based sample size calculations in microarray experiments , 2005, Bioinform..
[42] T. Kawabe,et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.
[43] A. Newton,et al. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.
[44] G. Mills,et al. Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.
[45] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[46] G. Mills,et al. Determinants of Rapamycin Sensitivity in Breast Cancer Cells , 2004, Clinical Cancer Research.
[47] L. Mulligan,et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. , 1999, The American journal of pathology.
[48] L. Peso,et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.
[49] S. R. Datta,et al. Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.
[50] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .